Steven ODay
Overview
Explore the profile of Steven ODay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
4677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilky B, Schwartz G, Gordon M, El-Khoueiry A, Bullock A, Henick B, et al.
J Clin Oncol
. 2025 Jan;
JCO2402524.
PMID: 39869830
Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define...
2.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2024 Mar;
4(3):785.
PMID: 38477691
No abstract available.
3.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2023 Dec;
3(12):2572-2584.
PMID: 38115208
Purpose: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ inhibitor) in combination with...
4.
Ellingsen E, ODay S, Mezheyeuski A, Gromadka A, Clancy T, Kristedja T, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3026-3036.
PMID: 37378632
Purpose: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in...
5.
Long G, Robert C, Butler M, Couture F, Carlino M, ODay S, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5280-5288.
PMID: 34210681
Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029...
6.
Bustos M, Gross R, Rahimzadeh N, Cole H, Tran L, Tran K, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33202891
Serum lactate dehydrogenase (LDH) is a standard prognostic biomarker for stage IV melanoma patients. Often, LDH levels do not provide real-time information about the metastatic melanoma patients' disease status and...
7.
Owsley J, Stein M, Porter J, In G, Salem M, ODay S, et al.
Exp Biol Med (Maywood)
. 2020 Oct;
246(1):31-39.
PMID: 33019809
These data represent the largest aggregation of BRAF mutations within a single clinical database to our knowledge. The relative proportions of both BRAF V600 mutations and non-V600 mutations are informative...
8.
In G, Poorman K, Saul M, ODay S, Farma J, Olszanski A, et al.
Oncotarget
. 2020 Sep;
11(33):3118-3128.
PMID: 32913556
Background: Brain metastases are a significant cause of mortality and morbidity for patients with melanoma. We hypothesize that the development of brain metastases may be explained by molecular heterogeneity between...
9.
Bustos M, Tran K, Rahimzadeh N, Gross R, Lin S, Shoji Y, et al.
Cancers (Basel)
. 2020 Jul;
12(6).
PMID: 32630542
Primary cutaneous melanoma frequently metastasizes to distant organs including the brain. Identification of cell-free microRNAs (cfmiRs) found in the blood can be used as potential body fluid biomarkers for detecting...
10.
Kim M, Parmar H, Schipper M, Devasia T, Aryal M, Kesari S, et al.
Int J Radiat Oncol Biol Phys
. 2020 Mar;
107(3):478-486.
PMID: 32169409
Purpose: To determine the recommended phase 2 dose of RRx-001, a radiosensitizer with vascular normalizing properties, when used with whole-brain radiation therapy (WBRT) for brain metastases and to assess whether...